Normal view MARC view ISBD view

Preventing and reversing vacuum-induced optical losses in high-finesse tantalum (V) oxide mirror coatings. [electronic resource]

By:

Gangloff, Dorian

Contributor(s):

Producer: 20150928Description: 18014-28 p. digitalISSN:

1094-4087

Online resources:

Available from publisher's website

In: Optics express vol. 23

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

No physical items for this record

Publication Type: Journal Article

There are no comments on this title.

to post a comment.

Back to results

1 Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications.
by Garrett, Joan T
2 Will PI3K pathway inhibitors be effective as single agents in patients with cancer?
by Garrett, Joan T
3 Genomic alterations of ERBB receptors in cancer: clinical implications.
by Mishra, Rosalin
4 Erratum: Will PI3K pathway inhibitors be effective as single agents in patients with cancer?
by Garrett, Joan T
5 HER3 signaling and targeted therapy in cancer.
by Mishra, Rosalin
6 Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.
by Miller, Todd W
7 Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.
by Garrett, Joan T
8 Current Advances in the Treatment of BRAF-Mutant Melanoma.
by Patel, Hima
9 Activating HER3 mutations in breast cancer.
by Mishra, Rosalin
10 An evaluation of the U.S. in-flight medical kit.
by DeJohn, Charles A
11 An evaluation of in-flight medical care in the U.S.
by DeJohn, Charles A
12 Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu.
by Garrett, Joan T
13 Utilization of Reactive Oxygen Species Targeted Therapy to Prolong the Efficacy of BRAF Inhibitors in Melanoma.
by Yuan, Long
14 Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo.
by Allen, Stephanie D
15 Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.
by Garrett, Joan T
16 Oxidative Cyclization-Induced Activation of a Phosphoinositide 3-Kinase Inhibitor for Enhanced Selectivity of Cancer Chemotherapeutics.
by Zhu, Haizhou
17 ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis.
by Cook, Rebecca S
18 Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase.
by Garrett, Joan T
19 LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.
by Schwarz, Luis J
20 Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.
by Kaumaya, Pravin T P